Cargando…
Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study
Background: extended anticoagulant therapy beyond the initial 6 months is suggested in patients with cancer-associated thrombosis (CAT) and active cancer. Few data are available on patient management and outcomes on the period between 6 and 12 months after the venous thromboembolism (VTE) event. Obj...
Autores principales: | Mahé, Isabelle, Plaisance, Ludovic, Chapelle, Céline, Laporte, Silvy, Planquette, Benjamin, Bertoletti, Laurent, Couturaud, Francis, Falvo, Nicolas, Falchero, Lionel, Mahé, Isild, Helfer, Hélène, Chidiac, Jean, Meyer, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463918/ https://www.ncbi.nlm.nih.gov/pubmed/32806574 http://dx.doi.org/10.3390/cancers12082256 |
Ejemplares similares
-
Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study
por: Plaisance, Ludovic, et al.
Publicado: (2021) -
Management of Cancer-Associated Thrombosis in France: A National Survey among Vascular Disease and Supportive Care Specialists
por: Mahé, Isabelle, et al.
Publicado: (2022) -
In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients
por: Poénou, Géraldine, et al.
Publicado: (2022) -
Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
por: Poénou, Géraldine, et al.
Publicado: (2023) -
Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
por: Mayenga, Marie, et al.
Publicado: (2023)